Cost-effectiveness of Prophylactic Zika Virus Vaccine in the Americas
A. Shoukat et al.
(University of Texas Medical Branch at Galveston) Researchers from The University of Texas Medical Branch at Galveston showed, for the first time, that a single, higher dose of vaccination to a pregnant mouse safely protects both her and her fetus from the Zika virus.The researchers found that a single, less potent dose was not enough to protect the fetus. The findings are currently available in Nature Communications.
(University of Queensland) A new technology to produce safer 'hybrid' viruses at high volumes for use in vaccines and diagnostics for mosquito-borne diseases has been developed at The University of Queensland.Researchers from UQ and QIMR Berghofer Medical Research Institute have exploited the benign characteristics of the Binjari virus - inert to humans - to produce 'dangerous looking' mosquito-borne viruses such as Zika and dengue, but which cannot grow in humans or animals.
(American Association for the Advancement of Science) A research team has identified a new species of virus specific to insects that can be engineered to house genes from related viruses that cause diseases such as Zika and yellow fever.
Flaviviruses such as dengue, yellow fever, Zika, West Nile, and Japanese encephalitis virus present substantial global health burdens. New vaccines are being sought to address safety and manufacturing issues associated with current live attenuated vaccines. Here, we describe a new insect-specific flavivirus, Binjari virus, which was found to be remarkably tolerant for exchange of its structural protein genes (prME) with those of the aforementioned pathogenic vertebrate-infecting flaviviruses (VIFs). Chimeric BinJ/VIF-prME viruses remained replication defective in vertebrate cells but replicated with high efficiency in mosq...
Canadian Journal of Microbiology, e-First Articles. Zika virus (ZIKV) is a mosquito-borne virus that was first isolated from Zika forest, Uganda, in 1947. Since its inception, major and minor outbreaks have been documented from several parts of world. Aedes spp. mosquitoes are the primary vectors of ZIKV, but the virus can also be transmitted through sexual practices, materno-fetal transmission, and blood transfusion. The clinical presentations of symptomatic ZIKV infections are similar to dengue and chikungunya, including fever, headache, arthralgia, retro-orbital pain, conjunctivitis, and rash. ZIKV often causes mild ill...
Zika virus outbreaks have been explosive and unpredictable and have led to significant adverse health effects —as well as considerable public anxiety. Significant scientific work has resulted in multiple candidate vaccines that are now undergoing further clinical development, with several vaccines now in phase 2 clinical trials. In this review, we survey current vaccine efforts, preclinical and clinical r esults, and ethical and other concerns that directly bear on vaccine development. It is clear that the world needs safe and effective vaccines to protect against Zika virus infection.
As the need to fairly address pregnant women ’s health interests in vaccine research is increasingly recognized, it is necessary to understand attitudes regarding research participation during pregnancy. Through the lens of hypothetical Zika virus vaccine trials, we sought to characterize how different forms and levels of evidence affect wom en’s perceptions about enrollment in vaccine research during pregnancy.
Lu Lu Recently, Zika virus (ZIKV) has attracted much attention in consideration of its association with severe neurological complications including fetal microcephaly. However, there are currently no prophylactic vaccines or therapeutic drugs approved for clinical treatments of ZIKV infection. To determine the potential anti-ZIKV inhibitors, we screened a library of clinical drugs with good safety profiles. Erythromycin estolate (Ery-Est), one of the macrolide antibiotics, was found to effectively inhibit ZIKV infection in different cell types and significantly protect A129 mice from ZIKV-associated neurological sign...
(Integral Molecular) The NIH has awarded Integral Molecular a contract which will provide up to $5.5M over the next five years to define antibody responses to pathogenic viruses including Zika, Marburg and equine encephalitis viruses (EEV), aiding the discovery of vaccines and therapeutics against these currently untreatable and often lethal viruses.